These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33299059)

  • 21. Myeloablative treatments for multiple myeloma: update of a comparative study of different regimens used in patients from the Spanish registry for transplantation in multiple myeloma.
    Lahuerta JJ; Grande C; Blade J; Martínez-López J; de la Serna J; Alegre A; Garcia LJ; Caballero D; de la Rubia J; Marín J; Perez-Lopez C; Sureda A; Escudero A; Cabrera R; Conde E; García-Ruiz JC; Pérez-Equiza K; Hernandez F; Palomera L; León A; Giraldo P; Solano C; Bargay J; San MJ;
    Leuk Lymphoma; 2002 Jan; 43(1):67-74. PubMed ID: 11908738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk factors of early disease progression and decreased survival for multiple myeloma patients after upfront autologous stem cell transplantation.
    Hsu TL; Tsai CK; Liu CY; Yeh CM; Lin FL; Hsiao LT; Liu YC; Chien SH; Wang HY; Ko PS; Lin TA; Chen WC; Chen PM; Liu JH; Gau JP; Liu CJ
    Ann Hematol; 2024 Aug; 103(8):2893-2904. PubMed ID: 38472362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase 1 trial of autologous stem cell transplantation conditioned with melphalan 200 mg/m
    Patel P; Oh AL; Koshy M; Sweiss K; Saraf SL; Quigley JG; Khan I; Mahmud N; Hacker E; Ozer H; Peace DJ; Weichselbaum RR; Aydogan B; Rondelli D
    Leuk Lymphoma; 2018 Jul; 59(7):1666-1671. PubMed ID: 29065747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras.
    Li AY; Atenafu EG; Bernard RS; Masih-Khan E; Reece D; Franke N; Tiedemann R; Prica A; Trudel S; Kukreti V; Chen CI
    Bone Marrow Transplant; 2020 Mar; 55(3):578-585. PubMed ID: 31558786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.
    Marini C; Maia T; Bergantim R; Pires J; Aguiar E; Guimarães JE; Trigo F
    Ann Hematol; 2019 Feb; 98(2):369-379. PubMed ID: 30368589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study.
    Park SS; Kim K; Kim SJ; Lee JH; Yoon SS; Mun YC; Lee JJ; Eom HS; Kim JS; Min CK;
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1312-1319. PubMed ID: 30910603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
    Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
    Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
    Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
    Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning.
    Ursu SG; Maples S; Williams KJ; Patrus G; Samhouri Y; Fazal S; Mewawalla P; Sadashiv S
    J Hematol; 2023 Oct; 12(5):201-207. PubMed ID: 37936977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma.
    Miller KC; Gertz MA; Buadi FK; Hayman SR; Wolf RC; Lacy MQ; Dispenzieri AA; Dingli D; Kapoor P; Gonsalves WI; Kourelis T; Hogan WJ; Kumar SK
    Bone Marrow Transplant; 2019 Apr; 54(4):587-594. PubMed ID: 30116014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Final outcomes of escalated melphalan 280 mg/m
    Hari P; Reece DE; Randhawa J; Flomenberg N; Howard DS; Badros AZ; Rapoport AP; Meisenberg BR; Filicko-Ohara J; Phillips GL; Vesole DH
    Bone Marrow Transplant; 2019 Feb; 54(2):293-299. PubMed ID: 29907806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis.
    Song GY; Jung SH; Lee JJ; Kim JS; Min CK; Kim K; Choi Y; Eom HS; Joo YD; Kim SH; Kwak JY; Kang HJ; Lee JH; Lee HS; Mun YC; Moon JH; Sohn SK; Park SK; Park Y; Shin HJ; Yoon SS
    Leuk Lymphoma; 2020 Nov; 61(11):2714-2721. PubMed ID: 32580672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
    Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
    Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era.
    Li Y; Zhang X; Zou Z; Xiong Y; Gu X; Zou R; Tan J; Zhang L; Zheng Y; Niu T
    Clin Exp Med; 2024 Sep; 24(1):215. PubMed ID: 39249542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
    Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.
    Palumbo A; Bringhen S; Bruno B; Falcone AP; Liberati AM; Grasso M; Ria R; Pisani F; Cangialosi C; Caravita T; Levi A; Meloni G; Nozza A; Pregno P; Gabbas A; Callea V; Rizzo M; Annino L; De Stefano V; Musto P; Baldi I; Cavallo F; Petrucci MT; Massaia M; Boccadoro M
    Blood; 2010 Mar; 115(10):1873-9. PubMed ID: 19965659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation.
    Al Saleh AS; Sidiqi MH; Muchtar E; Buadi FK; Dispenzieri A; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
    Biol Blood Marrow Transplant; 2020 Aug; 26(8):1402-1405. PubMed ID: 32422250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma.
    Barta SK; Jain R; Mazumder A; Carter J; Almanzar L; Browne R; Shahnaz S; Elkind R; Kaminetzky D; Battini R; Derman O; Kornblum N; Verma A; Braunschweig I
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):650-657. PubMed ID: 28684379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.